外周血基因表达特征诊断亚临床急性排斥反应
本研究基于GoCAR前瞻性队列,对肾移植受者3个月监测活检时全血进行RNA测序,识别出与亚临床或交界性急性细胞性排斥反应(ACR-3)相关的17基因特征,并在独立队列中验证其可无创诊断亚临床急性排斥反应并风险分层。
要点
- 17基因外周血特征可无创诊断肾移植后3个月亚临床急性排斥反应。
- ACR-3患者后续12和24个月临床急性排斥风险更高、移植物功能下降更快、移植物存活更差。
- 靶向表达检测可识别持续急性排斥和未来移植物丢失高风险个体。
核心结论
- 基于17基因的靶向表达检测可实现亚临床急性排斥反应和移植物炎症的无创诊断,并可能有助于肾移植受者的风险分层。
研究设计与样本
- 前瞻性GoCAR队列中88例受者在3个月监测活检时采集全血行RNA测序以识别与ACR-3相关的转录本,并开发基于测序的靶向表达检测。
- 在独立队列110例受者中验证17基因特征的靶向表达检测。
- 利用GoCAR队列65例受者血液微阵列表达谱及三个公共微阵列数据集验证17基因特征。
主要发现
- ACR-3患者较无ACR-3者后续12和24个月临床急性排斥风险显著更高,移植物功能下降更快,调整Cox分析显示移植物存活降低。
- 外周血17基因特征可准确诊断ACR-3。
- 独立队列中基于17基因的靶向表达检测可识别持续急性排斥和未来移植物丢失风险更高的个体。
关键数值与推荐
- 17基因特征用于诊断移植后3个月亚临床或交界性急性细胞性排斥反应(ACR-3)。
临床怎么用
- 对于稳定肾移植受者,可考虑使用外周血17基因靶向表达检测无创评估亚临床急性排斥反应风险,以减少监测活检需求并指导风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In kidney transplant recipients, surveillance biopsies can reveal, despite stable graft function, histologic features of acute rejection and borderline changes that are associated with undesirable graft outcomes. Noninvasive biomarkers of subclinical acute rejection are needed to avoid the risks and costs associated with repeated biopsies. METHODS: We examined subclinical histologic and functional changes in kidney transplant recipients from the prospective Genomics of Chronic Allograft Rejection (GoCAR) study who underwent surveillance biopsies over 2 years, identifying those with subclinical or borderline acute cellular rejection (ACR) at 3 months (ACR-3) post-transplant. We performed RNA sequencing on whole blood collected from 88 individuals at the time of 3-month surveillance biopsy to identify transcripts associated with ACR-3, developed a novel sequencing-based targeted expression assay, and validated this gene signature in an independent cohort. RESULTS: Study participants with ACR-3 had significantly higher risk than those without ACR-3 of subsequent clinical acute rejection at 12 and 24 months, faster decline in graft function, and decreased graft survival in adjusted Cox analysis. We identified a 17-gene signature in peripheral blood that accurately diagnosed ACR-3, and validated it using microarray expression profiles of blood samples from 65 transplant recipients in the GoCAR cohort and three public microarray datasets. In an independent cohort of 110 transplant recipients, tests of the targeted expression assay on the basis of the 17-gene set showed that it identified individuals at higher risk of ongoing acute rejection and future graft loss. CONCLUSIONS: Our targeted expression assay enabled noninvasive diagnosis of subclinical acute rejection and inflammation in the graft and may represent a useful tool to risk-stratify kidney transplant recipients.
引用
- Zhang W, Yi Z, Keung KL, et al. A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. J Am Soc Nephrol. 2019. PMID: 31278196. doi:10.1681/ASN.2018111098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。